Rhumbline Advisers Day One Biopharmaceuticals, Inc. Call Options Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DAWN
# of Institutions
178Shares Held
84MCall Options Held
144KPut Options Held
218K-
Ra Capital Management, L.P. Boston, MA7.87MShares$108 Million1.53% of portfolio
-
Atlas Venture Life Science Advisors, LLC6.43MShares$88.2 Million11.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.89MShares$80.8 Million0.0% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$66.9 Million1.92% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$62.2 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $1.01B
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...